Related Experiment Video

Updated: Oct 2, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

678

Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with

Marianna Puccini1, Christian Rauch1, Kai Jakobs1,2

  • 1Charité Center 11-Department of Cardiology, Charité-University Medicine, Berlin, Germany.

Cardiovascular Drugs and Therapy
|February 25, 2022
PubMed

Insights

Overweight and obese patients with chronic coronary syndrome (CCS) show increased platelet reactivity despite dual antiplatelet therapy (DAPT). This suggests a need for further research into more potent antiplatelet agents for these individuals.

Area of Science:

  • Cardiology
  • Hematology
  • Obesity Medicine

Background:

  • Obesity is linked to heightened platelet reactivity and diminished response to antiplatelet medications.
  • Chronic coronary syndrome (CCS) patients often require dual antiplatelet therapy (DAPT) to prevent thrombotic events.

Purpose of the Study:

  • To assess platelet reactivity using impedance aggregometry in overweight and obese patients with CCS undergoing DAPT.
  • To compare platelet reactivity between normal weight and overweight/obese CCS patients on DAPT.

Main Methods:

  • Platelet aggregation was measured via impedance aggregometry in CCS patients on aspirin plus clopidogrel.
  • Comparison of platelet reactivity between normal weight and overweight/obese groups.
  • Analysis of the correlation between body mass index (BMI) and platelet aggregation induced by adenosine diphosphate (ADP) and thrombin receptor-activating peptide (TRAP).

Main Results:

  • Overweight and obese patients exhibited significantly higher adenosine diphosphate- (ADP-) and thrombin receptor-activating peptide- (TRAP-) dependent platelet reactivity compared to normal weight patients.
  • A positive correlation was found between body mass index (BMI) and agonist-induced platelet reactivity.
  • The study included 64 patients, with 35.9% being normal weight.

Conclusions:

  • Overweight and obese patients with CCS demonstrate elevated platelet reactivity even when on DAPT.
  • Future clinical trials are necessary to determine if these patients would benefit from more potent antiplatelet inhibitors.
Abstract

Keywords:
AggregometryDual antiplatelet therapyObesityOverweightPlatelet function

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.3K
Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.1K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
680
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
44
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
58
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
53
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
56
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.4K